Leerink Partners Initiates Coverage On Mind Medicine with Outperform Rating, Announces Price Target of $20

-4.20% Post

Mind Medicine Inc Ordinary Shares (Sub Voting)

MNMD

0.00

Leerink Partners analyst Rudy Li initiates coverage on Mind Medicine (NASDAQ: MNMD) with a Outperform rating and announces Price Target of $20.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

AI Boom or Bubble: Should You Buy, Hold, or Sell Your Tech Stocks

Breaking News | Stocks Rise at Open, US Govt Shutdown Averted

Nasdaq +1.8%, SanDisk Soars 9%, Xpeng Jumps 12% — AI & Chip Stocks Lead Massive Comeback as U.S. Shutdown Deal Nears

A Fresh Look at Macy's (M) Valuation as Investor Optimism Builds

How DartPoints Partnership May Shift Nutanix's (NTNX) Position in Regulated Cloud Markets

Pre-Bell Movers | SLRX Gains Substantial Momentum by 69.4%; Here Are 20 Stocks Moving Premarket

In One Chart | AMD Reaffirms Strong Growth in AI-Related Spending - What Happened to Top 20 US Stocks by Turnover on November 13th

AMD Jumps 9%. Shorts Waiting? Hmm... What's It Really Worth by the Cash Flow?